Heather Minto1, Kofi A Mensah2, Paul R Reynolds1, Eric Meffre2, Kira Rubtsova3, Erwin W Gelfand4. 1. Immunodeficiency Diagnosis and Treatment Program, Department of Pediatrics, National Jewish Health, Denver, CO 80206, United States. 2. Department of Immunobiology and Division of Rheumatology, Yale University School of Medicine, New Haven, CT 06511, United States. 3. Department of Biomedical Research, National Jewish Health, Denver, CO 80206, United States. 4. Immunodeficiency Diagnosis and Treatment Program, Department of Pediatrics, National Jewish Health, Denver, CO 80206, United States. Electronic address: erwin3460@gmail.com.
Abstract
Ataxia-Telangiectasia (AT) is an immunodeficiency most often associated with T cell abnormalities. We describe a patient with a hyper-IgM phenotype and immune cell abnormalities that suggest a distinct clinical phenotype. Significant B cell abnormalities with increased unswitched memory B cells, decreased naive transitional B cells, and an elevated frequency of CD19+CD38loCD27-CD10-CD21-/low B cells expressing high levels of T-bet and Fas were demonstrated. The B cells were hyporesponsive to in vitro stimulation through the B cell receptor, Toll like receptors (TLR) 7 and 9, and CD40. T cell homeostasis was also disturbed with a significant increase in γδ T cells, circulating T follicular helper cells (Tfh), and decreased numbers of T regulatory cells. The ATM mutations in this patient are posited to have resulted in the perturbations in the frequencies and distributions of B and T cell subsets, resulting in the phenotype in this patient. KEY MESSAGES: A novel mutation creating a premature stop codon and a nonsense mutation in the ATM gene are postulated to have resulted in the unique clinical picture characterized by abnormal B and T cell populations, lymphocyte subset dysfunction, granuloma formation, and a hyper-IgM phenotype. CAPSULE SUMMARY: A patient presented with ataxia-telangiectasia, cutaneous granulomas, and a hyper-IgM phenotype; a novel combination of mutations in the ATM gene was associated with abnormal distributions, frequencies, and function of T and B lymphocyte subsets.
Ataxia-Telangiectasia (AT) is an immunodeficiency most often associated with T cell abnormalities. We describe a patient with a hyper-IgM phenotype and immune cell abnormalities that suggest a distinct clinical phenotype. Significant B cell abnormalities with increased unswitched memory B cells, decreased naive transitional B cells, and an elevated frequency of CD19+CD38loCD27-CD10-CD21-/low B cells expressing high levels of T-bet and Fas were demonstrated. The B cells were hyporesponsive to in vitro stimulation through the B cell receptor, Toll like receptors (TLR) 7 and 9, and CD40. T cell homeostasis was also disturbed with a significant increase in γδ T cells, circulating T follicular helper cells (Tfh), and decreased numbers of T regulatory cells. The ATM mutations in this patient are posited to have resulted in the perturbations in the frequencies and distributions of B and T cell subsets, resulting in the phenotype in this patient. KEY MESSAGES: A novel mutation creating a premature stop codon and a nonsense mutation in the ATM gene are postulated to have resulted in the unique clinical picture characterized by abnormal B and T cell populations, lymphocyte subset dysfunction, granuloma formation, and a hyper-IgM phenotype. CAPSULE SUMMARY: A patient presented with ataxia-telangiectasia, cutaneous granulomas, and a hyper-IgM phenotype; a novel combination of mutations in the ATM gene was associated with abnormal distributions, frequencies, and function of T and B lymphocyte subsets.
Authors: Martin S Naradikian; Arpita Myles; Daniel P Beiting; Kenneth J Roberts; Lucas Dawson; Ramin Sedaghat Herati; Bertram Bengsch; Susanne L Linderman; Erietta Stelekati; Rosanne Spolski; E John Wherry; Christopher Hunter; Scott E Hensley; Warren J Leonard; Michael P Cancro Journal: J Immunol Date: 2016-07-18 Impact factor: 5.422
Authors: Mirzokhid Rakhmanov; Baerbel Keller; Sylvia Gutenberger; Christian Foerster; Manfred Hoenig; Gertjan Driessen; Mirjam van der Burg; Jacques J van Dongen; Elisabeth Wiech; Marcella Visentini; Isabella Quinti; Antje Prasse; Nadine Voelxen; Ulrich Salzer; Sigune Goldacker; Paul Fisch; Hermann Eibel; Klaus Schwarz; Hans-Hartmut Peter; Klaus Warnatz Journal: Proc Natl Acad Sci U S A Date: 2009-07-29 Impact factor: 11.205
Authors: Lukas Bossaller; Jan Burger; Ruth Draeger; Bodo Grimbacher; Rolf Knoth; Alessandro Plebani; Anne Durandy; Ulrich Baumann; Michael Schlesier; Andrew A Welcher; Hans Hartmut Peter; Klaus Warnatz Journal: J Immunol Date: 2006-10-01 Impact factor: 5.422
Authors: David A Lammas; E De Heer; J D Edgar; V Novelli; A Ben-Smith; R Baretto; P Drysdale; J Binch; C MacLennan; D S Kumararatne; S Panchalingam; T H M Ottenhoff; J-L Casanova; J F Emile Journal: Int J Exp Pathol Date: 2002-02 Impact factor: 1.925
Authors: Alexander Schwarz; Bettina Balint; Mirjam Korporal-Kuhnke; Sven Jarius; Kathrin von Engelhardt; Alexandra Fürwentsches; Cornelia Bussmann; Friedrich Ebinger; Brigitte Wildemann; Jürgen Haas Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-12-15
Authors: Ana Coraglia; Nora Galassi; Diego S Fernández Romero; M Cecilia Juri; Marta Felippo; Alejandro Malbrán; María M E de Bracco Journal: J Immunol Res Date: 2016-03-16 Impact factor: 4.818
Authors: Amarilla B Mandola; Brenda Reid; Raga Sirror; Rae Brager; Peter Dent; Pranesh Chakroborty; Dennis E Bulman; Chaim M Roifman Journal: Front Immunol Date: 2019-12-20 Impact factor: 7.561
Authors: Anna K Meyer; Mindy Banks; Tibor Nadasdy; Jennifer J Clark; Rui Zheng; Erwin W Gelfand; Jordan K Abbott Journal: Front Pediatr Date: 2019-10-24 Impact factor: 3.418